Potential Health Economic Impact of Intravenous Iron Supplementation to Erythropoiesis-Stimulating Agent Treatment in Patients with Cancer- or Chemotherapy-Induced Anemia | Citedby Results | Oncology | Karger Publishers

Skip to Main Content

Skip Nav Destination

Potential Health Economic Impact of Intravenous Iron Supplementation to Erythropoiesis-Stimulating Agent Treatment in Patients with Cancer- or Chemotherapy-Induced Anemia

Oncology (2011) 81 (1): 45–49.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency

Iain C. Macdougall
Josep Comin-Colet
Christian Breymann
Donat R. Spahn
Ioannis E. Koutroubakis

Advances in Therapy (2020) 37 (5): 1960.

Management of anemia in patients with cancer: 2019 Italian Association of Medical Oncology (AIOM) guidelines

Andrea Sbrana
Andrea Antonuzzo
Antonella Brunello
Fausto Petrelli
Paolo Pronzato
Antonino Tralongo
Marianna Turrini
Federica Zoratto
Marco Danova

Tumori Journal (2020) 106 (5): 337.

A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment

Richard F. Pollock
Gorden Muduma

Expert Review of Hematology (2019) 12 (2): 129.

Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status

Jorge Eduardo Toblli
Federico Di Gennaro
Christophe Mariat

PLOS ONE (2015) 10 (4): e0125528.

Iron sucrose – characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas

Yves Beguin
Aurélie Jaspers

Expert Opinion on Pharmacotherapy (2014) 15 (14): 2087.

Evaluation of a Single Dose of Ferric Carboxymaltose in Fatigued, Iron-Deficient Women – PREFER a Randomized, Placebo-Controlled Study

Bernard Favrat
Katharina Balck
Christian Breymann
Michael Hedenus
Thomas Keller
Anna Mezzacasa
Christoph Gasche
James F. Collins

PLoS ONE (2014) 9 (4): e94217.

Iron Deficiency Anemia—Bridging the Knowledge and Practice Gap

Aryeh Shander
Lawrence T. Goodnough
Mazyar Javidroozi
Michael Auerbach
Jeffrey Carson
William B. Ershler
Mary Ghiglione
John Glaspy
Indu Lew

Transfusion Medicine Reviews (2014) 28 (3): 156.

Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS)

G. R. Bailie
M. Larkina
D. A. Goodkin
Y. Li
R. L. Pisoni
B. Bieber
N. Mason
L. Tong
F. Locatelli
M. R. Marshall
M. Inaba
B. M. Robinson

Nephrology Dialysis Transplantation (2013) 28 (10): 2570.

Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece

Eleftheria Nikolaidi
Magdalini Hatzikou
Mary Geitona

Cost Effectiveness and Resource Allocation (2013) 11 (1): 16.

An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic

Paul D. Wilson
Adam Hutchings
Aruna Jeans
Iain C. Macdougall

Journal of Medical Economics (2013) 16 (1): 108.

Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey

Diego Cortinovis
Giordano Beretta
Elena Piazza
Giovanna Luchena
Stefania Aglione
Alessandro Bertolini
Roberto Buzzoni
Mary Cabiddu
Carlo Carnaghi
Marco Danova
Gabriella Farina
Vittorio Ferrari
Mara Frascaroli
Michele Reni
Giuseppe Tansini

Tumori Journal (2013) 99 (1): 45.

Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

Matti Aapro
Paul Cornes
Diana Sun
Ivo Abraham

Therapeutic Advances in Medical Oncology (2012) 4 (3): 95.